$32.30
-0.30-0.92%
At close: Jan 13, 4:00 PM EST
$32.30
-0.30-0.92%
Pre-Market: 4:05 AM EST
Comments
Loading...
Upstream Bio Analyst Ratings and Price Targets | NASDAQ:UPB | Benzinga
Upstream Bio Inc has a consensus price target of $49 based on the ratings of 8 analysts. The high is $75 issued by Piper Sandler on November 5, 2024. The low is $38 issued by JP Morgan on November 5, 2024. The 3 most-recent analyst ratings were released by Mizuho, LifeSci Capital, and Evercore ISI Group on December 18, 2025, December 2, 2025, and November 18, 2025, respectively. With an average price target of $44.67 between Mizuho, LifeSci Capital, and Evercore ISI Group, there's an implied 38.29% upside for Upstream Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Mizuho
LifeSci Capital
Evercore ISI Group
Truist Securities
JP Morgan
1calculated from analyst ratings
Analyst Ratings for Upstream Bio
FAQ
What is the target price for Upstream Bio (UPB) stock?
The latest price target for Upstream Bio (NASDAQ:UPB) was reported by Mizuho on December 18, 2025. The analyst firm set a price target for $51.00 expecting UPB to rise to within 12 months (a possible 57.89% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Upstream Bio (UPB)?
The latest analyst rating for Upstream Bio (NASDAQ:UPB) was provided by Mizuho, and Upstream Bio initiated their outperform rating.
When was the last upgrade for Upstream Bio (UPB)?
There is no last upgrade for Upstream Bio
When was the last downgrade for Upstream Bio (UPB)?
There is no last downgrade for Upstream Bio.
When is the next analyst rating going to be posted or updated for Upstream Bio (UPB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Upstream Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Upstream Bio was filed on December 18, 2025 so you should expect the next rating to be made available sometime around December 18, 2026.
Is the Analyst Rating Upstream Bio (UPB) correct?
While ratings are subjective and will change, the latest Upstream Bio (UPB) rating was a initiated with a price target of $0.00 to $51.00. The current price Upstream Bio (UPB) is trading at is $32.30, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
